Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Comparator-Controlled, Double-Blind, Multicenter Study to Evaluate the Immunogenicity, Safety and Lot to Lot Consistency of Three Lots of a PIKA Rabies Vaccine（Vero Cell）for Human Use,Freeze-dried in Healthy Adults Using a Post-Exposure Prophylaxis Schedule

NCT05667974 is registered in ClinicalTrials.gov with Yisheng Biopharma (Singapore) Pte. Ltd. as lead sponsor.

NCT NCT05667974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05667974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Comparator-Controlled, Double-Blind, Multicenter Study to Evaluate the Immunogenicity, Safety and Lot to Lot Consistency of Three Lots of a PIKA Rabies Vaccine（Vero Cell）for Human Use,Freeze-dried in Healthy Adults Using a Post-Exposure Prophylaxis Schedule
Lead sponsor
Yisheng Biopharma (Singapore) Pte. Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
September 22, 2023
Completion date
February 21, 2025
Enrollment
4,500 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

prevention, rabies